Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

STAT-Diagnostica Appoints Board Chairman

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Company names Gérard Vaillant as chairman of the company’s board of directors.

STAT-Diagnostica has appointed Gérard Vaillant as chairman of the company’s board of directors. With more than three decades of senior leadership experience in the medical device and diagnostics sector, he brings expert industry perspective and guidance to the company as it prepares for the successive European and U.S. launches of its novel DiagCORE Near Patient Testing platform.

Vaillant is a career veteran of Johnson & Johnson Worldwide who has held of number of senior executive positions within the organization.

These include managing director, Ortho Clinical Diagnostics France (1981 - 1987); vice president, Johnson & Johnson International (1987 - 1992); worldwide president, LifeScan, a Johnson & Johnson company (1992 - 1995); and company group chairman, Diagnostics Worldwide (1995 - 2004).

He was also a member of Johnson & Johnson’s Medical Devices and Diagnostic Group Operating Committee until retiring in 2004.

After his retirement from Johnson & Johnson, he remained active in the industry as board member of both Luminex and Vivacta.

In addition to his current position with STAT-Diagnostica, Vaillant currently serves as chairman of the board of SafeOrthopaedics and PathoQuest; board member of Tecan CH; and venture partner at KLS Partners.

“We are very privileged to have Gérard join as the chairman of our board of directors,” said Jordi Carrerra, CEO and co-founder of STAT-Diagnostica.

Carrerra continued, “His deep industry pedigree and proven track record of success will be invaluable to us as we move towards European and U.S. approval and commercialization of our DiagCORE platform.”

Vaillant joins STAT-Diagnostica following the company’s closing of a Series B financing round totaling $22.1 million/17 million Euros, which was announced May 6, 2013.

Led by new investor Kurma Life Sciences Partners, the round also drew participation from new investors Idinvest; Boehringer Ingelheim Venture Fund; and, Caixa Capital Risc, the venture capital division of “la Caixa;” as well as existing investors Ysios Capital and Axis.

The proceeds of the funding are being used to complete development of the company’s DiagCORE platform and clinical validation of its first products.

“The DiagCORE platform represents a significant breakthrough in the area of Near Patient Testing that stands to change clinical practice in the critical care setting,” said Vaillant.

Vaillant continued, “In addition to its unique technology, STAT-Diagnostica’s excellent leadership and strong investor support are what attracted me to the board chairman position. I look forward to being part of the company’s future success.”

STAT-Diagnostica’s DiagCORE Near Patient Testing platform is designed to simplify and reduce time to results for the diagnosis of certain medical conditions.

The in vitro diagnostic system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device.

The first clinical applications will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.

STAT-Diagnostica’s DiagCORE platform not only offers multi-analyte and multi-sample capabilities, but it also reduces current diagnosis times (which can take up to several days) by providing results in less than 30 minutes.

The system’s rapid performance will enable improved clinical decision making by medical practitioners, delivering better patient management with direct and indirect savings to the healthcare system.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos